Microbial Biotherapeutics: From Probiotics to Engineered Bacteria in Modern Pharmaceutical Practice

M. M. Zeina Haider Abbas

1. Introduction:

The pharmaceutical landscape is undergoing a fundamental transformation with the emergence of microbial biotherapeutics-live microorganisms developed to prevent, treat, or cure human diseases. Moving beyond conventional pharmacology, this field

leverages the intrinsic biological activities of bacteria, marking a convergence of microbiology, synthetic biology, and clinical medicine. Once limited to over-the-counter probiotic supplements, microbial therapeutics now encompass clinically validated, standardized, and engineered products poised to enter mainstream medical practice (O’Toole et al., 2017). This transition reflects a broader understanding of the human microbiome as an essential organ with profound pharmacological implications (Zmora et al., 2018).

2. First Generation: Probiotics and Defined Microbial Consortia

Probiotics represent the foundational class of microbial biotherapeutics, traditionally consumed as food supplements containing live Lactobacillus or Bifidobacterium strains.

Mechanisms of Action: Their benefits are attributed to:

Direct Antagonism: Production of bacteriocins and organic acids that inhibit pathogens (Cotter et al., 2013).

Barrier Enhancement: Strengthening of intestinal epithelial tight junctions via induction of protective mucins and proteins (Sicard et al., 2017).

Immune Modulation: Interaction with gut-associated lymphoid tissue to promote anti-inflammatory cytokine profiles and regulatory T-cell differentiation (Hardy et al., 2013).

Clinical Evidence: Strongest evidence supports specific strains for managing antibiotic-associated diarrhea (e.g.,Saccharomyces boulardii) and pouchitis (Szajewska & Kołodziej, 2015). However, effects are often strain-specific and transient.

Limitations: Lack of targeted delivery, susceptibility to gastric acid, and variable colonization due to inter-individual microbiome differences pose significant challenges for consistent therapeutic outcomes (Suez et al., 2019).

Figure 1 Probiotic lactic acid bacteria with bacteriocin production exhibit several functions: inhibiting pathogens, colonizing through competitive exclusion, activating macrophages and NK cells to induce apoptosis in cancer cells, immunomodulation, balancing the gut-brain axis, and demonstrating antiobesity effects by reducing adipose tissue.

3. Second Generation: Engineered Microbial Therapeutics (EMTs)

Synthetic biology has enabled the design of “smart” bacteria with enhanced or novel functionalities. These EMTs are engineered as precise drug-delivery vehicles (Riglar & Silver, 2018).

Core Design Principles:

1.Tumor-Targeting Bacteria: Anaerobic or facultative anaerobic bacteria (e.g., Salmonella typhimurium, E. coli) are engineered to selectively colonize hypoxic tumor cores. They are further modified to locally produce cytotoxic agents (e.g., 

cytolysin), anti-angiogenic factors, or immune checkpoint inhibitors, minimizing systemic toxicity (Gurbatri et al., 2020).

2.Sense-and-Respond Systems: Bacteria are programmed with genetic circuits to detect disease biomarkers (e.g., quorum-sensing molecules from pathogens, inflammation-associated tetrathionate) and respond by producing a therapeutic payload only in the diseased microenvironment (Mimee et al., 2016).

3. Metabolic Engineering: Strains are designed to perform therapeutic functions, such as consuming harmful metabolites (e.g., Lactococcus lactis engineered to degrade ammonia in hyperammonemia) or synthesizing essential nutrients in situ (e.g., phenylalanine ammonia-lyase for phenylketonuria) (Isabella et al., 2018).

 4. Delivery and Formulation Challenges

The transition from lab to clinic requires overcoming significant pharmaceutical hurdles.
Viability and Stability: Ensuring bacterial survival during manufacturing, lyophilization, storage, and passage through the gastrointestinal tract demands advanced formulation technologies, such as microencapsulation (Cook et al., 2021).

Targeted Colonization: Controlling bacterial localization and persistence to avoid off-target effects remains a key engineering challenge, often addressed by coupling tissue-specific adhesion proteins (Piñero-Lambea et al., 2015).

Containment Strategies: Implementing genetic “kill switches” (e.g., dependency on an exogenous nutrient, induced lysis circuits) is crucial to ensure environmental safety and prevent uncontrolled proliferation (Chan et al., 2016).

Regulatory Classification: Defining these living entities as drugs, biologics, or a new regulatory category, with stringent requirements for characterization, potency, and purity, presents an evolving challenge for agencies like the FDA and EMA (Brennan, 2018).

5. Clinical Pipeline and Future Directions

The microbial biotherapeutics pipeline is rapidly expanding.

Oncology: Phase I/II trials are underway for engineered Clostridium novyi-NT (spores that germinate in tumors) and Salmonella strains for solid tumors (Zhou et al., 2018).

Metabolic Diseases: SYNB1618 (an engineered E. coli for phenylketonuria) has completed early-phase trials, demonstrating proof-of-concept for in vivo metabolite consumption (Isabella et al., 2018).

Infectious Diseases: Engineered bacteriophages and bacteria expressing phage lysins are in development for decolonizing multi-drug resistant pathogens like MRSA and C. difficile (Ando et al., 2015).

Future Outlook: Next-generation designs focus on multi-strain consortia performing complex functions, bacteria delivering mRNA or gene-editing tools (e.g., CRISPR-Cas), and microbiome-editing therapies for chronic inflammatory diseases (Bober et al., 2022).

References

Ando, H., Lemire, S., Pires, D. P., & Lu, T. K. (2015). Engineering modular viral scaffolds for targeted bacterial population editing. Cell Systems, 1(3), 187-196.

Bober, J. R., Beisel, C. L., & Nair, N. U. (2022). Synthetic biology approaches to engineer probiotics and members of the human microbiota for biomedical applications. Annual Review of Biomedical Engineering, 24, 125-149.

Brennan, A. M. (2018). Regulatory considerations for live biotherapeutic products. Cell Host & Microbe, 23(6), 725-727.

Chan, C. T., Lee, J. W., Cameron, D. E., Bashor, C. J., & Collins, J. J. (2016). Deadman and Passcode microbial kill switches for bacterial containment. Nature Chemical Biology, 12(2), 82-86.

Cook, M. T., Tzortzis, G., Charalampopoulos, D., & Khutoryanskiy, V. V. (2021). Microencapsulation of probiotics for gastrointestinal delivery. Journal of Controlled Release, 162(1), 56-67.

Cotter, P. D., Ross, R. P., & Hill, C. (2013). Bacteriocins-a viable alternative to antibiotics? Nature Reviews Microbiology, 11(2), 95-105.

Gurbatri, C. R., Arpaia, N., & Danino, T. (2020). Engineering bacteria as interactive cancer therapies. Science, 368(6491), 587-591.

Hardy, H., Harris, J., Lyon, E., Beal, J., & Foey, A. D. (2013). Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients, 5(6), 1869-1912.

Isabella, V. M., Ha, B. N., Castillo, M. J., et al. (2018). Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nature Biotechnology, 36(9), 857-864.

Mimee, M., Tucker, A. C., Voigt, C. A., & Lu, T. K. (2016). Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Systems, 2(3), 207-216.

O’Toole, P. W., Marchesi, J. R., & Hill, C. (2017). Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nature Microbiology, 2(5), 1-6.

Piñero-Lambea, C., Ruano-Gallego, D., & Fernández, L. Á. (2015). Engineered bacteria as therapeutic agents. Current Opinion in Biotechnology, 35, 94-102.
Riglar, D. T., & Silver, P. A. (2018). Engineering bacteria for diagnostic and therapeutic applications. Nature Reviews Microbiology, 16(4), 214-225.

Sicard, J. F., Le Bihan, G., Vogeleer, P., Jacques, M., & Harel, J. (2017). Interactions of intestinal bacteria with components of the intestinal mucus. Frontiers in Cellular and Infection Microbiology, 7, 387.

Suez, J., Zmora, N., Segal, E., & Elinav, E. (2019). The pros, cons, and many unknowns of probiotics. Nature Medicine, 25(5), 716-729.

Szajewska, H., & Kołodziej, M. (2015). Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Alimentary Pharmacology & Therapeutics, 42(7), 793-801.

Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018). Tumour-targeting bacteria engineered to fight cancer. Nature Reviews Cancer, 18(12), 727-743.

Zmora, N., Zilberman-Schapira, G., Suez, J., et al. (2018). Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell, 174(6), 1388-1405.